Survival analysis over a 20-year period of a Brazilian cohort of blood donors coinfected HIV-HCV

Imagem de Miniatura
Arquivos
art_MENEZES FILHO_Survival_analysis_over_a_20year_period_of_a_2023.PDF (370.58 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
GRANDI, Giuliano
CARDOSO, Ludimila Paula Vaz
SILVA, Juan Felipe Galvao da
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.27, n.5, article ID 102810, 6p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Among individuals coinfected with HCV and HIV, studies of mortality from non-hepatic causes have shown inconsistent results. The aim of this study was to investigate the contribution of HCV and HIV co-infection to mortality from hepatic and non-hepatic causes in Brazil. This retrospective cohort study included blood donors from Funda & ccedil;& atilde;o Pr & oacute;-Sangue de S & atilde;o Paulo (FPS) who were followed from 1994 to 2016 to compare mortality and its causes between HIV-HCV coinfected individuals versus those seronegative for all tested infections. Records from the FPS database and the Mortality Information System were linked through a probabilistic record Relationship (RL). The Hazard Ratio (HR) was estimated using Cox multiple regression models. HCV-HIV coinfected individuals compared to seronegative individuals had a higher risk of death from all causes (HR = 14.54), non-liver neoplasms (HR = 2.55), infections (HR = 10.37) and liver disease (HR = 7.0). In addition, HCV mono-infected individuals compared to seronegative individuals had a higher risk of death from all causes (HR = 2.23), liver cancer (HR = 32.21), liver disease (HR = 14.92), infection (HR = 3.22), and trauma (HR = 1.68). Individuals coinfected with HCV and HIV have increased overall mortality and death due to infections, liver diseases and non-liver neoplasms as compared to those uninfected with HCV and HIV.
Palavras-chave
Hepatitis C, HIV, Mortality
URI
https://observatorio.fm.usp.br/handle/OPI/57436
Referências
  1. Alejos B, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004727
  2. Allison RD, 2015, J HEPATOL, V63, P822, DOI 10.1016/j.jhep.2015.04.021
  3. Amin J, 2006, LANCET, V368, P938, DOI 10.1016/S0140-6736(06)69374-4
  4. Bang CS, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0606-9
  5. Benzaken AS, 2019, BRAZ J INFECT DIS, V23, P182, DOI 10.1016/j.bjid.2019.04.010
  6. Brazil, 2004, Age^ncia Nacional de Vigila^ncia Sanitaria. Legislaca~o em Vigila^ncia Sanitaria _Resoluca~o-RDC n.o 153 de 4 de junho de 2004
  7. Brazil, 2016, Ministerio da Saude. Portaria N.O 158 De 04 De Fevereiro De 2016
  8. Brazil, 2004, Doencas Infecciosas e Parasitarias: Guia de Bolso, VII
  9. Brazil, 2021, Ministerio da Saude. Secretaria de Vigila^ncia em Saude, Departamento de Doencas de Condico~es Cro^nicas e Infecco~es Sexualmente Transmissiveis. Boletim Epidemiologico HIV/ AIDS. Numero Especial
  10. Camargo K R Jr, 2000, Cad Saude Publica, V16, P439
  11. Capuani L, 2014, CAD SAUDE PUBLICA, V30, P1623, DOI 10.1590/0102-311X00024914
  12. Chalouni M, 2021, J HEPATOL, V74, P37, DOI 10.1016/j.jhep.2020.08.008
  13. Chebrolu P, 2015, AM J MED SCI, V349, P217, DOI 10.1097/MAJ.0000000000000391
  14. da Cunha CC, 2017, EPIDEMIOL SERV SAUDE, V26, P19, DOI [10.5123/s1679-49742017000100003, 10.5123/S1679-49742017000100003]
  15. Uehara SND, 2016, BRAZ J INFECT DIS, V20, P205, DOI 10.1016/j.bjid.2015.12.003
  16. Domingues CMAS, 2012, REV INST MED TROP SP, V54, pS22, DOI 10.1590/S0036-46652012000700009
  17. Duberg AS, 2008, J VIRAL HEPATITIS, V15, P538, DOI 10.1111/j.1365-2893.2008.00982.x
  18. Filho HRdM, 2019, PLoS One, V14
  19. Franca E, 2008, INT J EPIDEMIOL, V37, P891, DOI 10.1093/ije/dyn121
  20. Gjærde LI, 2016, CLIN INFECT DIS, V63, P821, DOI 10.1093/cid/ciw380
  21. Goyal A, 2021, J VIRAL HEPATITIS, V28, P334, DOI 10.1111/jvh.13429
  22. Grebely J, 2011, J VIRAL HEPATITIS, V18, P32, DOI 10.1111/j.1365-2893.2010.01279.x
  23. Guiltinan AM, 2008, AM J EPIDEMIOL, V167, P743, DOI 10.1093/aje/kwm370
  24. Hall T, 2020, AIDS RES HUM RETROV, V36, P193, DOI [10.1089/aid.2019.0113, 10.1089/AID.2019.0113]
  25. Hung CI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168202
  26. Jackson ML, 2004, CLIN INFECT DIS, V39, P1642, DOI 10.1086/425615
  27. Kim YC, 2017, INFECT CHEMOTHER, V49, P268, DOI 10.3947/ic.2017.49.4.268
  28. Klein MB, 2014, AIDS, V28, P1957, DOI 10.1097/QAD.0000000000000377
  29. Kovari H, 2015, J HEPATOL, V63, P573, DOI 10.1016/j.jhep.2015.04.019
  30. Kristiansen MG, 2011, J VIRAL HEPATITIS, V18, P237, DOI 10.1111/j.1365-2893.2010.01290.x
  31. Kronfli N, 2019, AIDS, V33, P1013, DOI 10.1097/QAD.0000000000002156
  32. Lee MH, 2012, J INFECT DIS, V206, P469, DOI 10.1093/infdis/jis385
  33. Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
  34. Neal KR, 2007, GUT, V56, P1098, DOI 10.1136/gut.2006.113217
  35. Pisano MB, 2021, WORLD J GASTROENTERO, V27, P4018, DOI 10.3748/wjg.v27.i26.4018
  36. Platt L, 2016, LANCET INFECT DIS, V16, P797, DOI 10.1016/S1473-3099(15)00485-5
  37. Sangue, 2018, Manual de Transfusa
  38. Santos ME, 2020, AIDS BEHAV, V24, P1069, DOI 10.1007/s10461-019-02585-7
  39. Schnell R, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-41
  40. Wu PH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001328
  41. Yu A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-291

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03